(Q56986459)

English

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

A D'Addio

1

0 references

A Curti

2

0 references

N Worel

3

0 references

K Douglas

4

0 references

M R Motta

5

0 references

S Rizzi

6

0 references

E Dan

7

0 references

S Taioli

8

0 references

V Giudice

9

0 references

H Agis

10

0 references

G Kopetzky

11

0 references

R Soutar

12

0 references

B Casadei

13

0 references

M Baccarani

14

0 references

R M Lemoli

15

0 references

language of work or name

0 references

publication date

March 2011

0 references

Bone Marrow Transplantation

0 references

46

0 references

3

0 references

356-63

0 references

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Improving stem cell mobilization strategies: future directions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Treatment of newly diagnosed myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

21 January 2018

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

7 January 2021

based on heuristic

inferred from DOI database lookup

Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic stem cell mobilization

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

7 January 2021

based on heuristic

inferred from DOI database lookup

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL st

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

7 January 2021

based on heuristic

inferred from DOI database lookup

Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.128

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2010.128

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56986459&oldid=2213218001"